Know Cancer

or
forgot password

Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Small Cell Lung Cancer

Thank you

Trial Information

Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer


Inclusion Criteria:



- Provision of written informed consent

- Histologically confirmed, relapsed or refractory SCLCr

- Aged 18 or over and a life expectancy of more than 2 months

Exclusion Criteria:

- Any evidence of clinically active interstitial lung disease

- Other co-existing malignancies or malignancies diagnosed within the last 5 years,
with the exception of basal cell carcinoma or cervical cancer in situ.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the disease control rate in these patients

Principal Investigator

AstraZeneca Iressa Medical Science Director, MD

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca

Authority:

Denmark: Danish Medicines Agency

Study ID:

1839IL/0559

NCT ID:

NCT00298688

Start Date:

September 2004

Completion Date:

March 2007

Related Keywords:

  • Small Cell Lung Cancer
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

Name

Location